These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7170839)

  • 21. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice.
    Hernandez M; Wright SD; Cai TQ
    Biochem Biophys Res Commun; 2007 Apr; 355(4):1075-80. PubMed ID: 17335774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential hypolipidemic agents. IX. Heterocyclic compouns related to methyl clofenapate.
    Gronowitz S; Svenson R; Bondesson G; Magnusson O; Stjernström NE
    Acta Pharm Suec; 1974 Jun; 11(3):211-24. PubMed ID: 4839733
    [No Abstract]   [Full Text] [Related]  

  • 23. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
    Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential hypolipidemic agents. 8. 2-Chloro-5-piperidinosulphono-3-thiophenecarboxylic acids.
    Dafgård B; Gronowitz S; Bondesson G; Magnusson O; Stjernström NE
    Acta Pharm Suec; 1974 Jun; 11(3):309-12. PubMed ID: 4839741
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effects of clofibrate, Isopharm, on fat tolerance in atherosclerotic patients].
    Passowicz L
    Pol Tyg Lek; 1972 Jul; 27(30):1163-6. PubMed ID: 5073024
    [No Abstract]   [Full Text] [Related]  

  • 26. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
    Staels B; Van Tol A; Fruchart JC; Auwerx J
    Isr J Med Sci; 1996 Jun; 32(6):490-8. PubMed ID: 8682657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Animal models for screening hypolipidemic agents. I. Response to clofibrate in NMRI-mice of different body-weights.
    Magnusson O
    Z Versuchstierkd; 1978; 20(1):35-40. PubMed ID: 636681
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xanthone analogues of clofibrate / Synthesis and biological evaluation as antagonists of lipolysis in vitro.
    Gaion RM; Valenti P; Montanari P; Da Re P
    Arzneimittelforschung; 1982; 32(5):499-502. PubMed ID: 7201826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on serum lipoproteins of rats developing spontaneous hyperlipidemia.
    Gustafsson K; Kiessling H
    Artery; 1981; 9(6):456-76. PubMed ID: 7337554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
    Steger W
    Fortschr Med; 1980 May; 98(18):(718-20). PubMed ID: 7390386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
    Witiak DT; Kokrady SS; Patel ST; Huzoor Akbar H; Feller DR; Newmann HA
    J Med Chem; 1982 Jan; 25(1):90-3. PubMed ID: 7086828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of clofibrate on plasma lipid concentration and liver malic enzyme gene expression in rats with experimental chronic renal failure.
    Korczyńska J; Stelmańska E; Nieweglowski T; Szołkiewicz M; Rutkowski B; Swierczyński J
    Pol J Pharmacol; 2000; 52(4):291-7. PubMed ID: 11345485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-phenylpiperazine derivatives with hypocholesterolemic activity.
    Cascio G; Manghisi E; Porta R; Fregnan G
    J Med Chem; 1985 Jun; 28(6):815-8. PubMed ID: 4009605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacology and toxicology of etofylline clofibrate].
    Sterner W; Korn WD
    Arzneimittelforschung; 1980; 30(11b):2023-31. PubMed ID: 7194053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.